Precision Targeting GTPases in Cancer, Autoimmunity and Fibrosis

Precision Targeting GTPases in Cancer, Autoimmunity and Fibrosis

MBQ-167

Our lead compound, MBQ-167, is a first-in-class therapeutic which simultaneously inhibits both Rac and CDC42, removing pre-existing metastases. MBQ-167 is currently in its Phase-1 study.

Prevention of Metastatic Growth and Removal of Pre-Existing Metastases

  • Cancer mortality is closely linked to metastasis

  • Rac and Cdc42 are key genes in the development of metastasis

  • MBQ-167 is a first-in-class dual inhibitor of activation for Rac & Cdc42

  • MBQ-167 + Paclitaxel remove pre-existing metastases

  • MBQ Pharma leads in the science and development of Rac & Cdc42 inhibitors

We are the first

Why is the simultaneous inhibition of Rac and CDC42 so important? The simultaneous silencing of Rac and CDC42 genes can also be shown to remove pre-existing metastases. MBQ Pharma has licensed IP from the University of Puerto Rico covering families of compounds structurally optimized for their inhibition of Rac and CDC42.

This IP was developed from research by MBQ Pharma founders at the University of Puerto Rico. It includes precision targeted compounds inhibiting GTPases which regulate critical cell functions in the pathogenesis of cancer and metastasis. These compounds have also been shown to regulate angiogenesis and autoimmune and fibrotic chronic degenerative diseases.

Silencing Rac and Cdc42 genes after establishment of metastases removes metastatic tumors

Our Pipeline

Pipeline with differential selective GTPase inhibition profiles targeting cancer, metastasis and auto-immunity.

Compound Indication Preclinical Development Phase 1 Phase 2
MBQ-167 Breast Cancer
MBQ-167 Pancreatic Cancer
MBQ-167 Autoimmune Disease
MBQ-168 Pan-Cancer

A paradigm shift

The effective removal of pre-existing metastases will lead to the removal of solid tumor cancer as a major cause of death.

Our Partners